Nascent Biotech (NBIO) Short Interest Ratio & Short Volume → Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years (From Banyan Hill Publishing) (Ad) Free NBIO Stock Alerts $0.10 0.00 (0.00%) (As of 04/26/2024 ET) Add Compare Share Share Short InterestStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest Nascent Biotech Short Interest DataCurrent Short Volume17,900 sharesPrevious Short Volume14,700 sharesChange Vs. Previous Month+21.77%Dollar Volume Sold Short$3,302.55Short Interest Ratio / Days to Cover0.7Last Record DateMarch 31, 2024Today's Trading Volume0 sharesAverage Trading Volume79,815 sharesToday's Volume Vs. Average0% Short Selling Nascent Biotech ? Sign up to receive the latest short interest report for Nascent Biotech and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatNBIO Short Interest Over TimeNBIO Days to Cover Over TimeNBIO Percentage of Float Shorted Over Time Ad Banyan Hill PublishingForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)Watch my video for all of the details Nascent Biotech Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/31/202417,900 shares $3,302.55 +21.8%N/A0.7 $0.18 3/15/202414,700 shares $2,013.90 +61.5%N/A0.3 $0.14 2/29/20249,100 shares $941.85 +167.7%N/A0.1 $0.10 2/15/20243,400 shares $331.50 No ChangeN/A0 $0.10 12/31/20231,300 shares $224.77 No ChangeN/A0 $0.17 11/30/202317,900 shares $3,580.00 +67.3%N/A0.1 $0.20 Get the Latest News and Ratings for NBIO and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Nascent Biotech and its competitors with MarketBeat's FREE daily newsletter. 11/15/202310,700 shares $1,942.05 -55.6%N/A0 $0.18 10/31/202324,100 shares $3,566.80 -72.7%N/A0.1 $0.15 10/15/202388,400 shares $12,376.00 +4,320.0%N/A0.2 $0.14 9/30/20232,000 shares $251.60 No ChangeN/A0 $0.13 7/31/202310,900 shares $790.25 -47.6%N/A0 $0.07 7/15/202320,800 shares $1,549.60 No ChangeN/A0.1 $0.07 6/15/202327,400 shares $1,605.64 +270.3%N/A0 $0.06 5/31/20237,400 shares $331.52 -78.7%N/A0 $0.04 5/15/202334,800 shares $2,401.20 +222.2%N/A0 $0.07 4/30/202310,800 shares $651.24 No ChangeN/A0 $0.06 3/31/202323,200 shares $1,305.00 +127.5%N/A0 $0.06 3/15/202310,200 shares $789.48 -48.5%N/A0 $0.08 2/28/202319,800 shares $2,631.42 No ChangeN/A0.1 $0.13 1/31/20237,800 shares $1,076.40 +3,800.0%N/A0 $0.14 1/15/2023200 shares $27.75 -94.6%N/A0 $0.14 12/30/20223,700 shares $740.00 +3,600.0%N/A0 $0.20 12/15/2022100 shares $18.22 No ChangeN/A0 $0.18 11/30/2022100 shares $23.00 -98.7%N/A0 $0.23 11/15/20227,600 shares $1,896.20 -81.3%N/A0 $0.25 10/31/202240,700 shares $10,175.00 +307.0%N/A0.2 $0.25 10/15/202210,000 shares $2,709.00 +85.2%N/A0 $0.27 9/30/20225,400 shares $1,684.26 -82.1%N/A0 $0.31 9/15/202230,200 shares $12,080.00 -26.7%N/A0.1 $0.40 8/31/202241,200 shares $16,892.00 +2.5%N/A0.1 $0.41 8/15/202240,200 shares $16,863.90 +54.0%N/A0.1 $0.42 7/31/202226,100 shares $8,130.15 +289.6%N/A0.1 $0.31 7/15/20226,700 shares $1,792.25 -81.3%N/A0 $0.27 6/30/202235,800 shares $10,382.00 -27.8%N/A0 $0.29 6/15/202249,600 shares $10,907.04 +143.1%N/A0 $0.22 5/31/202220,400 shares $2,484.72 +11.5%N/A0.1 $0.12 5/15/202218,300 shares $2,016.66 +281.3%N/A0 $0.11 4/30/20224,800 shares $665.28 -85.4%N/A0 $0.14 4/15/202232,900 shares $3,783.50 +789.2%N/A0 $0.12 3/31/20223,700 shares $210.90 +311.1%N/A0 $0.06Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years (Ad)If you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)Watch my video for all of the details NBIO Short Interest - Frequently Asked Questions What is Nascent Biotech's current short interest? Short interest is the volume of Nascent Biotech shares that have been sold short but have not yet been closed out or covered. As of March 31st, traders have sold 17,900 shares of NBIO short. Learn More on Nascent Biotech's current short interest. What is a good short interest ratio for Nascent Biotech? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. NBIO shares currently have a short interest ratio of 1.0. Learn More on Nascent Biotech's short interest ratio. Is Nascent Biotech's short interest increasing or decreasing? Nascent Biotech saw a increase in short interest in March. As of March 31st, there was short interest totaling 17,900 shares, an increase of 21.8% from the previous total of 14,700 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: TC Energy Co. ($4.49 billion), T-Mobile US, Inc. ($3.94 billion), General Motors ($3.34 billion), Charter Communications, Inc. ($3.32 billion), Occidental Petroleum Co. ($3.21 billion), Super Micro Computer, Inc. ($3.13 billion), Coinbase Global, Inc. ($3.08 billion), Moderna, Inc. ($2.28 billion), Tractor Supply ($2.24 billion), and Royal Caribbean Cruises Ltd. ($2.14 billion). View all of the most shorted stocks. What does it mean to sell short Nascent Biotech stock? Short selling NBIO is an investing strategy that aims to generate trading profit from Nascent Biotech as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Nascent Biotech? A short squeeze for Nascent Biotech occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of NBIO, which in turn drives the price of the stock up even further. How often is Nascent Biotech's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including NBIO, twice per month. The most recent reporting period available is March, 31 2024. More Short Interest Resources from MarketBeat Related Companies: ATNFW Short Interest TRSBF Short Interest ABCZF Short Interest AGNPF Short Interest DRTSW Short Interest APLMW Short Interest ARTLW Short Interest ASPHF Short Interest ASCLF Short Interest AVCTF Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (OTCMKTS:NBIO) was last updated on 4/28/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressWhy Big Pharma is Investing Billions in This BiotechBehind the MarketsJeff Bezos Just Humiliated Elon MuskInvestorPlaceThe only accurate crypto trading system I know …Weiss Ratings